TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04296175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 90mg/m2, d1 every 2 or 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTX
Description: 600mg, d1 every 2 or 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80mg/m2,d1,d8,d15, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ddEpirubicin
Description: 90mg/m2, d1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ddCTX
Description: 600mg, d1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel(with carbo)
Description: 80mg/m2,d1,d8,d15, every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=2,d1,d8,d15, every 4 weeks
Study: NCT03979716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI examination

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI examination

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI examination
Study: NCT01145079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Description: Zotarolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus-eluting stent for ACS and DM
Description: Zotarolimus-eluting stent for ACS and DM

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent for long lesion
Description: Everolimus-eluting stent for long lesion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent for short lesion
Description: Sirolimus-eluting stent for short lesion
Study: NCT05265949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and physical activity intervention
Description: Dietary intervention: Preparation and follow-up of diet program Physical activity intervention: Step count monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and physical activity intervention
Description: Dietary intervention: Preparation and follow-up of diet program Physical activity intervention: Step count monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and physical activity intervention
Description: Dietary intervention: Preparation and follow-up of diet program Physical activity intervention: Step count monitoring
Study: NCT02442700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin
Description: Treatment A = administration pitavastatin for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin
Description: Treatment A = administration pitavastatin for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Treatment B = administration placebo for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Treatment B = administration placebo for 12 weeks
Study: NCT01581203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir (ASV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir (ASV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir (ASV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir (ASV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon alfa 2a (PegIFN)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon alfa 2a (PegIFN)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Study: NCT02170753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional manual therapy
Description: The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard physical therapy
Description: The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
Study: NCT00439140

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A injection into the detrusor.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A injection into the detrusor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A injection into the detrusor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A injection into the detrusor.

Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline (Placebo)
Description: Placebo (Normal Saline) injection into the detrusor.

Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline (Placebo)
Description: Placebo (Normal Saline) injection into the detrusor.
Study: NCT04595838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chemo Mouthpiece
Description: Frozen tube that fills the oral cavity used during and after chemotherapy to ease and prevent symptoms of oral mucositis

Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care only
Description: Standard Oral care for Chemotherapy
Study: NCT02012946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: patient receiving levosimendan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: patient receiving dobutamine
Study: NCT03553745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gentle Yoga Intervention
Description: 10-week exercise program structured around gentle yoga practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rigorous Yoga Intervention
Description: 10-week exercise program structured around rigorous yoga practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise Intervention
Description: 10-week exercise program structured around cardiovascular exercise.
Study: NCT00159523

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00834301

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Multivitamin
Description: Oral Multivitamin
Study: NCT01798446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib 5mg twice will be orally administered daily with one cycle of 4 weeks. The package of axitinib must be opened right before the administration due to its photosensitivity.
Study: NCT03544983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web + Streamlined Telephone Genetic Information
Description: Tailored and interactive web-based education designed to incorporate all aspects of standard genetic counseling followed by a streamlined genetic counseling session with a board-certified genetic counselor.
Study: NCT03835442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: baclofen 10mg tid for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo tid for 4 weeks
Study: NCT04638608

Intervention type: OTHER
Group type: OTHER
Intervention: EMBRACE (relatives)
Description: Online support program for both relatives

Intervention type: OTHER
Group type: OTHER
Intervention: EMBRACE (Health care providers)
Description: Online support program for health care providers
Study: NCT00053430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Tablet taken orally daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thalidomide placebo
Description: Placebo tablet taken orally daily
Study: NCT02201797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DCE MRI
Study: NCT02803710

Intervention type: OTHER
Intervention: Microbiological study

Intervention type: OTHER
Intervention: Microbiological study
Study: NCT00503035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg by mouth twice daily x 6 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy Biopsy
Description: Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure
Study: NCT03070327

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRt/BCMA-41BBz CAR T cell
Description: Modified T cell infusions will be administered 2-7 days following the completion of conditioning chemotherapy.There are 3 planned dose levels for this study: 1x10\^6, 3x10\^6, and 1x10\^7 EGFRt/BCMA-41BBz CAR T cells/kg, and a dose -1 level at 3x10\^5 EGFRt/BCMA-41BBz CAR T cells/kg, if needed; each dose cohort will consist of 3-6 patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 3000 mg/m2 IV once on day -7 to -2 or low intensity cy/flu (cyclophosphamide 300 mg/m2/day x 3 + fludarabine 30 mg/m2/day x 3) with the last day occurring on day -7 to -2 are the default options for is the default conditioning chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide.
Description: A cohort of patients will be treated with CAR T cell therapy and concomitant Lenalidomide. 10mg PO 21/28 days will be started no less then 1 week prior to clinical apheresis.
Study: NCT03138135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOME Study intervention
Description: Access to home HIV test kits, home STI self-collection kits, the HOME Study website, and the SexPro HIV risk assessment tool.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Counseling about the importance of quarterly HIV/STI testing and a PrEP information pamphlet.
Study: NCT02790619

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS via Chattanooga Ionto Iontophoresis System-Phoresor
Description: Small electrical current delivered non-invasively to the scalp. 1mA electrical current to Meditation and Active Stimulation 1 condition. 2mA to Meditation and Active 2 Stimulation condition.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS via Chattanooga Ionto Iontophoresis System-Phoresor
Description: Small electrical current delivered non-invasively to the scalp. 1mA electrical current to Meditation and Active Stimulation 1 condition. 2mA to Meditation and Active 2 Stimulation condition.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor
Description: Blinds participants to meditation condition by applying 30 seconds of real stimulation and then turning the device off.
Study: NCT02801838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: If the physician in charge of the patients judges it necessary, after the optimization of the ventilators settings, if the patient remains uncomfortable, a second therapeutic intervention using a maximum of 10mg morphine titration may be performed. After this second therapeutic intervention, a third non-verbal measure of respiratory discomfort will be performed with the IC-RDOS. Concomitantly, EEG and EMG will be again recorded over a of 15-minutes period.
Study: NCT04400175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valved ergonomic teat
Description: Administration of milk with a feeding system with a valved ergonomic teat in late preterm newborns.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Standard silicon teat
Description: Administration of milk with a feeding system with a standard silicon teat
Study: NCT03427788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2328065
Description: Doses from 2.25-700 mg once daily in an escalating manner as liquid service formulation (LSF) or tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, once daily in an escalating manner as LSF or tablets
Study: NCT00514501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodofiltic acid I 123
Study: NCT02651974

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: Patients will be mailed a control invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: Patients will be mailed a control invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cost condition
Description: Patients will be mailed a cost condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cost condition
Description: Patients will be mailed a cost condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cost/Future condition
Description: Patients will be mailed a cost/future condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cost/Future condition
Description: Patients will be mailed a cost/future condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
Study: NCT00511329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin [rDNA origin] for injection
Description: Genotropin will be started at 0.3 mg/kg/week administered by daily subcutaneous injection. Doses will be increased by weight at each visit. Additionally, we will monitor IGF-1 levels at month 3, and 6 and adjust the Genotropin dose to maintain IGF-1 levels in the 50th -75th percentile for ages.
Study: NCT02080273

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colgate Cavity Protection toothpaste
Description: 0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Total toothpaste
Description: 0.32% sodium fluoride (1450 ppm NaF) and 0.3% triclosan. Colgate Total toothpaste is the active comparator toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parodontax toothpaste
Description: 1400 ppm sodium fluoride (NaF), Parodontax toothpaste is the active comparator toothpaste
Study: NCT02534610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: 120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: 120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.
Study: NCT03065881

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RETeval
Description: The RETeval device measures the retina's electrical response to light, called an electroretinogram (ERG). The standards body ISCEV \[1\] recommends collecting normative data for ERGs to provide waveforms and statistically relevant measurements representing the range of ERGs from people with normal vision. LKC Technologies provides this information with their UTAS product line and wishes to collect such a database for the newest device: the RETeval device. As the RETeval device uses a different electrode to measure the ERG, the normal data for the UTAS product line is not transferable to the RETeval device. Ophthalmic practitioners would also like ERG examples of specific retinal disorders to help diagnose patients with abnormal ERGs. The RETeval device is FDA cleared (K142567),

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RETeval
Description: The RETeval device measures the retina's electrical response to light, called an electroretinogram (ERG). The standards body ISCEV \[1\] recommends collecting normative data for ERGs to provide waveforms and statistically relevant measurements representing the range of ERGs from people with normal vision. LKC Technologies provides this information with their UTAS product line and wishes to collect such a database for the newest device: the RETeval device. As the RETeval device uses a different electrode to measure the ERG, the normal data for the UTAS product line is not transferable to the RETeval device. Ophthalmic practitioners would also like ERG examples of specific retinal disorders to help diagnose patients with abnormal ERGs. The RETeval device is FDA cleared (K142567),
Study: NCT04089267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPO
Study: NCT03126799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib plus Bevacizumab
Description: Erlotinib 150mg, po, daily, q 3weeks plus Bevacizumab 15mg/kg, IV, on D1 Q 3 weeks
Study: NCT03109613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Description: level changes as per arm description
Study: NCT03126799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib 150mg, po, daily, Q weeks
Study: NCT02845661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 1 was started from 0.9 µg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 2 was started from 1.0 µg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 3 was started from 1.1 µg/kg
Study: NCT04106791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed-loop system for vasopressor administration
Description: The closed-loop system' goal is to keep MAP within 5 mmHg of the predefined target MAP.
Study: NCT02199418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT00876317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib 60 mg
Description: Etoricoxib 60 mg per oz per day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib 90 mg
Description: Etoricoxib 90 mg per oz for 14 days
Study: NCT02645994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion
Description: Used to control intravenous propofol delivery with target plasma concentratioins changed manually

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Loop Anesthesia Delivery System
Description: Used to deliver propofol automatically titrated to achieve a target BIS 50, and maintain it between 40 and 60.
Study: NCT00594256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Description: Patients will undergo a one-week evaluation period, which will include a taper and discontinuation of any currently prescribed sedative/hypnotics, as well as baseline diagnostic, psychopathology, neurocognitive and polysomnographic measurements (see below for details). Hypnotic taper may be extended or abbreviated, depending on clinical judgment. Patients will then begin a 4-week trial of adjunctive Xyrem (sodium oxybate). Patients will begin at 4.5 g/night (in divided doses of 2.25 g, with 1st dose at bedtime and then 2nd dose four hours later). Dosage will increase by 1.5 g/day every week, until a dose of 9 g nightly is reached, or a patient cannot tolerate further dose escalations. Medication will be administered in divided dosage for the duration of the study. A three-week taper (by 3 g/day weekly) of sodium oxybate will follow the four-week trial of sodium oxybate.
Study: NCT01867034

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drug Eluting Stent
Description: Comparison of two stents to see which results in best outcome.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bare Metal Stent
Study: NCT01205724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: Single dose (low) administered intravenously (into the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: Single dose (medium) administered intravenously (into the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: Single dose (high) administered intravenously (into the vein)
Study: NCT03454438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Referral strategies
Description: Two referral strategies will be compared to usual care, i.e. the control group. Patients will be followed for one year.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Referral strategies
Description: Two referral strategies will be compared to usual care, i.e. the control group. Patients will be followed for one year.
Study: NCT02147808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: All subjects will receive two 250 mg telotristat etiprate tablets three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: All subjects will receive 3 mg (1.5 mL oral syrup \[2mg/mL\]).